The estimated Net Worth of W Bradford Smith is at least $1.88 Million dollars as of 9 January 2023. Mr. Smith owns over 3,729 units of Homology Medicines Inc stock worth over $13,224 and over the last 20 years he sold FIXX stock worth over $5,183. In addition, he makes $1,860,300 as Chief Financial Officer and Treasurer and Secretary at Homology Medicines Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Smith FIXX stock SEC Form 4 insiders trading
W has made over 29 trades of the Homology Medicines Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently he sold 3,729 units of FIXX stock worth $5,183 on 9 January 2023.
The largest trade he's ever made was exercising 26,000 units of Homology Medicines Inc stock on 14 February 2006 worth over $257,400. On average, W trades about 3,677 units every 123 days since 2005. As of 9 January 2023 he still owns at least 14,219 units of Homology Medicines Inc stock.
You can see the complete history of Mr. Smith stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
W. Bradford Smith biography
W. Bradford Smith is Chief Financial Officer, Treasurer and Secretary of the company. He has served as our Chief Financial Officer and Treasurer since April 2017 and our Secretary since July 2017. From March 2014 to April 2017, Mr. Smith was Chief Financial Officer of Ocular Therapeutix, Inc., a biopharmaceutical platform company. Prior to joining Ocular Therapeutix, Inc., Mr. Smith served as the Chief Financial Officer of OmniGuide, Inc., a medical device company, from July 2008 to March 2014. Mr. Smith holds a B.S. in Biology from Tufts University and an M.B.A. from the Whittemore School of Business and Economics at the University of New Hampshire.
What is the salary of W Smith?
As the Chief Financial Officer and Treasurer and Secretary of Homology Medicines Inc, the total compensation of W Smith at Homology Medicines Inc is $1,860,300. There are 3 executives at Homology Medicines Inc getting paid more, with Arthur Tzianabos having the highest compensation of $5,062,880.
How old is W Smith?
W Smith is 64, he's been the Chief Financial Officer and Treasurer and Secretary of Homology Medicines Inc since 2017. There are 2 older and 16 younger executives at Homology Medicines Inc. The oldest executive at Homology Medicines Inc is Steven Gillis, 67, who is the Independent Director.
What's W Smith's mailing address?
W's mailing address filed with the SEC is C/O LYRA THERAPEUTICS, INC., 480 ARSENAL WAY, WATERTOWN, MA, 02472.
Insiders trading at Homology Medicines Inc
Over the last 7 years, insiders at Homology Medicines Inc have traded over $108,214,465 worth of Homology Medicines Inc stock and bought 3,033,333 units worth $51,999,993 . The most active insiders traders include Steven Gillis, James Edeerfield Management..., and Kush Parmar. On average, Homology Medicines Inc executives and independent directors trade stock every 26 days with the average trade being worth of $106,785. The most recent stock trade was executed by Paul Alloway on 25 March 2024, trading 23,530 units of FIXX stock currently worth $21,883.
What does Homology Medicines Inc do?
homology medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.
What does Homology Medicines Inc's logo look like?
Complete history of Mr. Smith stock trades at Neurometrix, Ocular Therapeutix Inc, Homology Medicines Inc, and Lyra Therapeutics
Homology Medicines Inc executives and stock owners
Homology Medicines Inc executives and other stock owners filed with the SEC include:
-
Arthur Tzianabos,
President, Chief Executive Officer, Director -
Tim Kelly,
Chief Technical Operations Officer -
Albert Seymour,
Chief Scientific Officer -
W. Bradford Smith,
Chief Financial Officer, Treasurer and Secretary -
Dr. Arthur O. Tzianabos Ph.D.,
Pres, CEO & Director -
Dr. Albert Seymour Ph.D.,
Chief Scientific Officer -
W. Bradford Smith CPA, M.B.A.,
CFO & Treasurer -
Alise Reicin,
Independent Director -
Kush Parmar,
Independent Director -
Mary Thistle,
Independent Director -
Richard Gregory,
Independent Director -
Matthew Patterson,
Independent Director -
Steven Gillis,
Independent Director -
Jeffrey Poulton,
Director -
Gabriel Cohn,
Chief Medical Officer -
Cara Mayfield,
Director of Corp. Communications -
Dr. Deborah Kinch Ph.D.,
Chief Devel. Officer -
Dr. Julie Jordan M.D.,
Sr. VP and Head of Clinical Devel. & Operations -
Michael Blum M.B.A.,
Chief Commercial Officer -
Dr. Gabriel M. Cohn M.B.A., M.D.,
Chief Medical Officer -
Melissa Gelormini,
VP of HR -
Theresa McNeely,
Chief Communications Officer & Patient Advocate -
Dr. Paul Alloway J.D., Ph.D.,
Chief Legal Officer & Sec. -
Timothy P. Kelly M.B.A.,
Chief Operating Officer -
Dr. Saswati Chatterjee Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Ventures Iv, L.P.5 Am Co In...,
-
Ventures Iv, L.P.5 Am Partn...,
-
Institutes For Bio Medical ...,
-
Ventures, Llcvv Manager Llc...,
-
Holdings (Private) Ltd Full...,
-
Cameron Wheeler,
Director -
Siyamak Rasty,
Chief Operating Officer -
James Edeerfield Management...,
-
James Edeerfield Management...,
-
Venture Fund Viii, L.P.Arch...,
-
Springs Capital Management ...,
-
Venture Fund Viii, L.P.Arch...,
-
Charles Jr Michaud,
See Remarks -
Paul Alloway,
See Remarks -
Michael Lee Blum,
Chief Commercial Officer -
Julie Jordan,
Chief Medical Officer